Apollomics Inc. (NASDAQ:APLM) Sees Large Decline in Short Interest

Apollomics Inc. (NASDAQ:APLM) saw a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 12,471 shares, a decrease of 15.2% from the February 12th total of 14,705 shares. Approximately 1.1% of the shares of the stock are sold short. Based on an average daily volume of 5,401 shares, the days-to-cover ratio is presently 2.3 days. Based on an average daily volume of 5,401 shares, the days-to-cover ratio is presently 2.3 days. Approximately 1.1% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

A number of research firms have recently commented on APLM. Wall Street Zen upgraded Apollomics from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apollomics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Apollomics Trading Down 2.0%

APLM stock opened at $19.51 on Tuesday. Apollomics has a 12-month low of $3.66 and a 12-month high of $42.12. The business’s 50-day moving average is $19.97 and its 200 day moving average is $17.84.

Institutional Trading of Apollomics

An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC purchased a new position in shares of Apollomics Inc. (NASDAQ:APLM) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned approximately 0.40% of Apollomics as of its most recent filing with the Securities & Exchange Commission. 19.13% of the stock is currently owned by institutional investors.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.